OSR Health, Inc. (OSRH) stockholders approve all 2026 annual meeting proposals

Q: What was the quorum at OSRH’s August 7, 2026 annual meeting?

OSR Health, Inc. achieved a quorum with 21,088,120 shares represented, about 60.05% of the 35,118,692 common shares entitled to vote as of the July 8, 2026 record date.

Q: How many OSRH (OSRH) shares were outstanding on the 2026 record date?

On the July 8, 2026 record date, OSR Health, Inc. had 35,118,692 shares of common stock outstanding, each entitled to one vote at the August 7, 2026 annual meeting.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

OSR Health, Inc. reported results of its August 7, 2026 annual stockholder meeting. As of the July 8, 2026 record date, there were 35,118,692 common shares outstanding. A total of 21,088,120 shares, or 60.05% of shares entitled to vote, were represented, constituting a quorum.

Stockholders re-elected seven directors to serve until the 2027 annual meeting, with each nominee receiving more than 15.17 million votes “for” and roughly 0.12–0.13 million votes “withheld.” Stockholders also approved ratification of the independent auditor with 20,296,535 votes “for,” the advisory executive compensation proposal with 15,059,135 votes “for,” and an Authorized Shares Increase Proposal with 19,922,498 votes “for” versus 581,009 “against.”

Filing Explained

Stockholders approved a proposal to increase OSR Health’s authorized shares, but this 8-K reports no issuance of additional Common Stock; it therefore records approval of additional share capacity, not dilution already incurred by existing holders.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding on record date: 35,118,692 shares Shares represented at meeting: 21,088,120 shares Quorum percentage: 60.05% +3 more

6 metrics

Shares outstanding on record date 35,118,692 shares Common stock outstanding as of July 8, 2026 record date

Shares represented at meeting 21,088,120 shares Shares present in person or by proxy at August 7, 2026 meeting

Quorum percentage 60.05% Percentage of outstanding common shares represented at the meeting

Auditor ratification votes for 20,296,535 Votes in favor of Ratification of Independent Auditor Proposal

Executive compensation votes for 15,059,135 Votes in favor of Executive Compensation Proposal

Authorized share increase votes for 19,922,498 Votes in favor of Authorized Shares Increase Proposal

Key Terms

quorum, Emerging growth company, Authorized Shares Increase Proposal, Executive Compensation Proposal

4 terms

quorum financial

"representing approximately 60.05% of the outstanding shares of Common Stock entitled to vote at the Annual Meeting, were present in person or by proxy, constituting a quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Authorized Shares Increase Proposal financial

"The stockholders approved the Authorized Shares Increase Proposal by the votes set forth in the table below"

Executive Compensation Proposal financial

"The stockholders approved the Executive Compensation Proposal by the votes set forth in the table below"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/10/2026 - 11:09 AM Accepted by SEC EDGAR 08/10/2026 - 11:09 AM

FAQ

What was the quorum at OSRH’s August 7, 2026 annual meeting?

OSR Health, Inc. achieved a quorum with 21,088,120 shares represented, about 60.05% of the 35,118,692 common shares entitled to vote as of the July 8, 2026 record date.

Did OSRH (OSRH) stockholders re-elect all director nominees at the 2026 meeting?

Yes. All seven OSR Health, Inc. director nominees were re-elected, each receiving over 15.17 million votes “for” and roughly 0.12–0.13 million votes “withheld” at the 2026 annual meeting.

How did OSRH (OSRH) stockholders vote on ratifying the independent auditor?

Stockholders approved ratification of OSR Health, Inc.’s independent auditor with 20,296,535 votes “for,” 201,444 votes “against,” and 590,141 abstentions at the August 7, 2026 annual meeting.

What was the outcome of OSRH’s executive compensation (say-on-pay) vote?

OSR Health, Inc. stockholders approved the Executive Compensation Proposal, with 15,059,135 votes “for,” 83,113 votes “against,” and 161,533 abstentions at the August 7, 2026 annual meeting.

Was OSRH’s Authorized Shares Increase Proposal approved by stockholders?

Yes. OSR Health, Inc. stockholders approved the Authorized Shares Increase Proposal with 19,922,498 votes “for,” 581,009 votes “against,” and 584,613 abstentions at the 2026 annual meeting.

How many OSRH (OSRH) shares were outstanding on the 2026 record date?

On the July 8, 2026 record date, OSR Health, Inc. had 35,118,692 shares of common stock outstanding, each entitled to one vote at the August 7, 2026 annual meeting.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2026

OSR HEALTH, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-41390	84-5052822
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

10900 NE 4th Street, Suite 2300, Bellevue, WA		98004
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code (425) 635-7700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	OSRH	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share	OSRHW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders

On August 7, 2026, the Company held an annual meeting of its stockholders (the “Annual Meeting”). As of the close of business on July 8, 2026, the record date for the Annual Meeting, there were 35,118,692 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issued and outstanding, each of which was entitled to one vote with respect to each of the proposals presented at the Annual Meeting. A total of 21,088,120 shares of Common Stock, representing approximately 60.05% of the outstanding shares of Common Stock entitled to vote at the Annual Meeting, were present in person or by proxy, constituting a quorum. The proposals listed below are described in more detail in the Definitive Proxy Statement on Form DEF 14A filed by the Company with the SEC on July 16, 2026 (the “Proxy Statement”).

Director Proposal

At the Annual Meeting, stockholders re-elected seven (7) directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified. The final voting results were as follows:

	FOR	WITHHELD	RESULT
Kuk Hyoun Hwang	15,174,735	129,046	Elected
Jun Chul Whang	15,175,735	128,046	Elected
Alcide Barberis	15,185,385	118,396	Elected
Seng Chin Mah	15,170,280	133,501	Elected
Hyuk Joo Jee	15,174,735	129,046	Elected
Joong Myung Cho	15,170,315	133,466	Elected
Reto Fierz	15,179,965	123,816	Elected

Ratification of Independent Auditor Proposal

The stockholders approved the Ratification of Independent Auditor Proposal by the votes set forth in the table below:

FOR		AGAINST		ABSTAIN
20,296,535		201,444		590,141

Executive Compensation Proposal

The stockholders approved the Executive Compensation Proposal by the votes set forth in the table below:

FOR		AGAINST		ABSTAIN
15,059,135		83,113		161,533

Authorized Shares Increase Proposal

The stockholders approved the Authorized Shares Increase Proposal by the votes set forth in the table below:

FOR		AGAINST		ABSTAIN
19,922,498		581,009		584,613

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 10, 2026

OSR HEALTH, INC.

By:	/s/ Kuk Hyoun Hwang
	Name:	Kuk Hyoun Hwang
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents